Scar

Researchers are evaluating the drug 9MW3811 in a randomized, double-blind, placebo-controlled Phase II study involving patients with pathological scars. The study aims to assess the drug's safety, tolerability, pharmacokinetics, immunogenicity, and preliminary effectiveness in improving scar conditions. Participants will have scars that have not improved spontaneously in the past six months and meet certain severity criteria. Participants will receive multiple intravenous infusions of either low, middle, or high doses of 9MW3811 or a matching placebo according to the study protocol. The treatment phase includes administration over a period up to 12 weeks, with dosing schedules designed to monitor responses and side effects closely. The study compares the effects of the different dosage levels of 9MW3811 against placebo. During the study, participants will undergo regular assessments including modified Vancouver Scar Scale scoring, patient and observer scar evaluations, quality of life questionnaires, vital sign checks, physical exams, ECGs, and laboratory tests. Pharmacokinetic properties such as plasma concentration and antibody development will be monitored up to day 85. The study includes careful safety monitoring and will follow participants for up to 12 weeks after treatment begins.

This research aims to evaluate the safety and effectiveness of ELAPR002f injectable gel in adults with moderate to severe atrophic acne scars. These scars are flat or indented marks that remain after acne heals and can affect quality of life through reduced self-esteem and embarrassment. The study is a controlled, randomized trial including about 395 adults with scarring on both cheeks, conducted at multiple sites in the United States. Participants are divided into two cohorts. Cohort 1 receives ELAPR002f injectable gel openly, while Cohort 2 participants are randomly assigned to receive either ELAPR002f gel or a saline control via intradermal injections. Treatments are given on Days 1, 31, and 61. After the three treatment sessions over two months, participants are followed for up to 12 months to observe outcomes and any side effects. During the study, participants will have regular visits at a clinic or hospital for medical assessments, blood tests, and questionnaires to monitor their progress and any side effects. Researchers will measure the percentage of participants who achieve at least a 20% reduction in acne scar area and various safety parameters, including injection site responses and changes in vital signs and laboratory values. The total study duration for each participant can be up to 420 days.

This research aims to compare two types of purse-string closures used to close circular surgical wounds: intra-dermal and transcutaneous. The study focuses on scar appearance and post-operative complications, using a split wound model where each participant's wound is closed by both methods on different halves. Researchers want to see if these two closure techniques result in similar cosmetic outcomes and safety profiles using validated scar assessment tools. Participants will have their surgical wounds closed with both techniques, one on each half of the wound, with the side assignments randomized. Intra-dermal purse-string closure involves placing sutures under the skin surface, while transcutaneous purse-string closure places sutures through the skin surface. Both are cinched like a coin purse to close the wound. This study uses a randomized, evaluator-blinded design to compare the effectiveness of these methods. Participants will be followed for three months post-surgery, during which the scars will be evaluated using the Patient Observer Scar Assessment Scale (POSAS) and the trace-to-tape method to measure scar width. Researchers will also monitor and record any complications or adverse events during this time. The study requires participants to return for a follow-up visit to assess these outcomes and complete the study involvement.

This trial investigates the use of a tie-over bolster dressing to reduce scarring after surgery on the head and face. Researchers want to see if applying this special gauze over stitches on half of a surgical wound can improve healing and reduce scar formation. The study focuses on patients undergoing cutaneous surgery with primary closure on the head or neck, aiming to compare traditional stitches with this bolster dressing method. Participants will have their surgical wound closed with standard stitches on one side, while the other side will receive stitches plus a tie-over bolster dressing secured by non-absorbable sutures. This bolster applies pressure to stabilize the wound and reduce tension, which may help minimize scar appearance. The study uses a randomized, single-blind, split-wound design, allowing each participant to serve as their own control. During the study, participants will be assessed at 3 months post-surgery using the Patient Observer Scar Assessment Score (POSAS) to evaluate scar appearance from both observer and patient perspectives. Scar width will also be measured, and any complications or adverse events related to treatment will be recorded. Participants must be willing to return for follow-up visits to complete these outcome assessments and monitor healing progress.

Researchers are evaluating two ways of delivering autologous nanofat grafts to treat post-burn and traumatic atrophic scars. The study compares injections of nanofat grafts with microneedling combined with nanofat grafts to see which method better improves scar appearance. This interventional trial is sponsored by Alexandria University and focuses on adults with scars lasting more than six months. Participants will have two scars with similar properties treated differently: one scar or part of a large scar will receive nanofat graft injections, while the other scar or part will be treated with microneedling combined with nanofat grafts. Both treatments involve procedures using the patient's own nanofat tissue. The study is non-randomized and does not use masking. During the study, researchers will assess changes in the scars using the Patient and Observer Scar Assessment Scale (POSAS) six months after treatment. Participants must be adults aged 18 to 60 years with scars older than six months and not currently receiving other scar treatments. The study excludes certain types of scars and participants with specific medical conditions. The total follow-up period for outcomes is six months after the procedures.

Researchers are studying the use of the AVAVA Device, a 1550nm Non-Ablative Fractional Laser, to treat various dermatologic conditions including acne, acne scars, wrinkles, pigment lesions, and skin texture disorders. The study aims to collect and analyze patient feedback on their overall experience with the device treatment. The primary focus is on responses to post-treatment questionnaires, while secondary measures include evaluations by physicians and patients regarding improvements and side effects. Participants will receive treatment using the AVAVA Device targeting their dermatologic condition. The study includes follow-up periods at 3, 6, and 12 months after the final treatment to assess outcomes. During these times, trained dermatologists will review before and after images, and both physicians and subjects will complete satisfaction and clinical improvement scales. The treatment process involves digital photography and adherence to specific skincare and sun exposure guidelines. Throughout the study, participants will complete questionnaires immediately after treatment and during follow-up visits to report their experience and tolerance of the procedure, including pain levels. Researchers will monitor the skin's response and improvements over time through imaging and clinical assessments. The study requires participants to comply with study instructions, maintain consistent skincare, and attend scheduled visits. The total participation duration spans from initial treatment through 12 months of follow-up.

This research aims to understand how genes and environmental factors interact to influence the development of diseases. It focuses on pregnant women and their children from birth up to 18 years old, studying key health conditions like overweight and obesity in children. The study collects detailed lifestyle, family, clinical, and imaging data to explore the origins and long-term health impacts beginning in early life. Participants include pregnant women under 13 weeks of gestation living in Shenyang or nearby areas who plan to deliver at Shengjing Hospital. The study tracks biometric changes in fetuses weekly from the thirteenth week of pregnancy until birth, measures newborn weight, and analyzes gene expression in both mothers and their partners. It also monitors non-invasive prenatal testing results and collects biological samples from children and parents. Throughout the study, children are followed up to age 18 with periodic assessments of their intestinal flora, height, weight, and gene expression at multiple ages. Researchers collect various clinical data and biological samples during pregnancy and childhood to evaluate health outcomes. Participation involves ongoing data collection, clinical visits, and sample donations to monitor growth and development over many years.

Researchers are evaluating the effects of two different suturing techniques used during cesarean sections on the healing of the uterine scar and the development of isthmocele, a uterine niche. The study involves pregnant women undergoing cesarean delivery regardless of their pregnancy risk. It aims to compare clinical outcomes, ultrasound features, and molecular markers related to uterine scarring and inflammation, investigating whether barbed sutures improve healing compared to conventional smooth sutures. Participants will be randomly assigned to receive either a barbed absorbable monofilament suture or a conventional smooth multifilament absorbable suture for uterine closure after cesarean section. The barbed suture is a size 0 device with unidirectional spikes that do not require knots, while the conventional suture is size 1 polyglactin. Both techniques use a single-layer, endometrium-free repair method. The study includes follow-up assessments at six months and longer-term monitoring of perinatal outcomes in subsequent pregnancies. During the study, participants will be monitored for clinical outcomes and undergo ultrasound examinations to measure the presence and size of isthmocele at six months postpartum. Molecular markers of hypoxia and inflammation within the uterine cavity will be analyzed, along with assessments of uterine scar stiffness and myometrial texture patterns through ultrasound. The study also tracks symptoms related to isthmocele and evaluates risk factors over an average of two years. Perinatal outcomes in following pregnancies are observed for up to four years, with safety and healing closely followed throughout the study period.

The trial investigates the effect on appearance of post-surgical scars using two different microneedle patches containing small interfering RNA (siRNA). Researchers aim to compare daily application of the siSPARC microneedle patch versus the siSPARC + siLR4A microneedle patch in adults aged 21 to 75 who have undergone surgery. This phase 2, randomized, double-blind controlled study is conducted at a single center and sponsored by the National Skin Centre. Participants will apply one of the two microneedle patches daily for 8 weeks, with treatment randomly assigned to each scar site within the same individual. The patches contain short microneedles embedded with hydrolysed RNA designed to target scar tissue. Follow-up visits occur at Day 30 and Day 60 after starting treatment, each lasting about 30 to 60 minutes. During the study, researchers will assess scar elevation using a high-resolution 3D scanner, rate scars with the Vancouver Scar Scale and Scar Cosmesis Assessment and Rating scale, and collect patient-reported pain and itch levels using an 11-point scale. Photographic documentation will be taken at baseline and follow-ups. Safety monitoring includes side effect assessments. The primary outcome measure is scar elevation assessed over one year, with secondary outcomes including scar scale scores, symptom reports, and side effects.

Researchers are studying the effects of liquid petroleum jelly and extra virgin olive oil on itching and scarring in patients who have suffered scald burns. These burns can cause complications such as itching, hypertrophic scars, sleep disturbances, anxiety, depression, and decreased quality of life. The study aims to provide evidence on managing post-burn itching and hypertrophic scarring, which are common and troubling complications during the wound-healing process. Current treatment options have limited evidence, and no prior scientific studies have evaluated these two moisturizers specifically for burn-related symptoms. Participants will be randomly assigned to three groups: one applying liquid petroleum jelly, another applying extra virgin olive oil, and a control group receiving no application beyond standard institutional recommendations. Those in the treatment groups will massage 5-10 ml of the assigned product onto the burn area twice daily for three months, with application recorded in a follow-up form. Patients will be visited on the 15th day, and at the first, second, and third months to monitor progress. Throughout the study, patients will complete several assessments, including the 12-item itch severity scale and patient and observer scar assessment scales, with wound area photographs taken. Data will be collected at baseline, 15 days, and monthly up to three months. The research team will analyze the effects of the treatments on itching, dryness, hypertrophic scarring, and patient comfort. The total participation duration is approximately three months, with ongoing evaluation to help improve nursing care for burn patients.